Considering TGF‐β is a dominant factor in the development of AMD and macular fibrosis or atrophy (Wang et al., 2019), the mechanism of enhanced TGF‐β activity after anti‐VEGF by intravitreal injection may provide a new way to prevent the development of nAMD and macular fibrosis or atrophy. Here, TGFB1 is linked to Atrophy.